Brought to you by 
Transkaryotic Therapies in $66.5mm licensing deal with HMR
11 Mar 2005
Executive Summary
Transkaryotic Therapies (gene therapy) will license an undisclosed Gene Activation protein (possibly G-CSF) to Hoechst Marion Roussel for (uf)$20mm up front ($10mm licensing fee and $10mm equity). TKT will get $4.5mm in research (but TKT's 8/96 S-1 filing says that's $3mm a year for two years), $42mm in milestones, and estimated 12% royalties.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Transkaryotic Therapies in $66.5mm licensing deal with HMR
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice